Oxyntomodulin Inhibits Pancreatic Secretion Through the Nervous System in Rats

Anini, Younès; Jarrousse, C.; Chariot, J; Nagain, C.; Yanaihara, N; Sasaki, Kohsuke; Bernad, Nicole; D, Le Nguyen; Bataille, D.; Rozé, C

doi:10.1097/00006676-200005000-00003

Cited by 32 publications

(25 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…On the other hand, inhibition of CCK-stimulated secretion by PYY in a half maximal dose of 250 pmol/ kg/h was not attributable to a hormonal action. The different responses of 2-DG-and CCK-stimulated pancreatic secretion to PYY, as confirmed recently [54], appear to indicate two different target sites for PYY. Since PYY does not inhibit CCK-8-and urecholine-stimulated amylase secretion from isolated dog and rat pancreatic acini [55], it has been postulated that its inhibitory effect is indirect and may be neural mediated.…”

Section: Peptide Tyrosine Tyrosylamide (Pyy)supporting

confidence: 63%

Neural hormonal regulation of exocrine pancreatic secretion

Chey¹,

Chang²

2001

Pancreatology

View full text Add to dashboard Cite

Section: Peptide Tyrosine Tyrosylamide (Pyy)supporting

confidence: 63%

Neural hormonal regulation of exocrine pancreatic secretion

Chey¹,

Chang²

2001

Pancreatology

View full text Add to dashboard Cite

“…It has been reported that GLP-1, CCK, PYY and other gut hormones can inhibit the release of ghrelin through vagus nerve stimulation. [34][35][36] Recombinant OXM in the intestinal tract may also stimulate the vagus nerve, followed by inhibition of ghrelin release by acting on its receptors. Further experiments are required to elucidate the mechanisms by which OXM exerts its effects on food intake and energy expenditure by oral administration.…”

Section: Discussionmentioning

confidence: 99%

Bifidobacterium as an oral delivery carrier of oxyntomodulin for obesity therapy: inhibitory effects on food intake and body weight in overweight mice

et al. 2010

View full text Add to dashboard Cite

Introduction: Oxyntomodulin (OXM) is a gut hormone released from intestinal L cell. Synthetic OXM and its analog reduce food intake and body weight in both rodents and human beings by being administered intravenously. However, people find intravenous administration difficult because of its side effects and inconvenience. The aim of this study is to develop a novel oral delivery system for OXM and its analog using genetically engineered Bifidobacterium as the carrier. Methods: An OXM gene expression vector pBBADs-OXM for the Bifidobacterium genus was constructed. Human OXM sequence was fused with extracellular exo-xylanase (XynF) signal peptide (Xs) from Bifidobacterium longum under the control of the pBAD promoter. B. longum NCC2705 was transformed with the recombinant plasmid pBBADs-OXM by electroporation, and the transformed B. longum was selected using MRS plates containing 60 mg ml À1 ampicillin. The OXM expression in vitro was identified by western blot and enzyme-linked immunosorbent assay (ELISA) assay after L-arabinose induction. Overweight BALB/c mice were treated with B. longum transformed with OXM after 0.2% L-arabinose induction every day for 4 weeks to investigate the effects of OXM-transformed B. longum on food intake and body weight by oral administration. The B. longum transformed with the green fluorescent protein (GFP) gene was used as negative control; orlistat, a gastrointestinal lipase inhibitor, was used as positive control; Normal saline (NS, 0.9% saline) was used as blank control. The food intakes of each group were measured every day, and body weights were measured once a week. Normal BALB/c (2 months old) mice were treated with OXM-transformed B. longum after induction by intragastric administration every day for 6 days to reveal the mechanism of transformed B. longum, with OXM exerting its biological function by oral administration. Plasma OXM, plasma ghrelin and the OXM of intestinal contents were detected by the ELISA method. Plasma glucose and triglyceride levels were analyzed using the Automatic Biochemistry Analyzer. Results: Transformed B. longum with OXM was selected and identified without biological and morphological alteration. An approximately 4-5 kDa OXM peptide was detected in both the supernatant and the cell pellet of transformed B. longum after L-arabinose induction in vitro. The food intake, body weight and blood triglyceride level of overweight mice treated with OXMtransformed B. longum were all significantly reduced compared with that of the GFP negative control group and NS control group (Po0.01). Interestingly, the plasma triglyceride level of the GFP group was significantly decreased compared with that of the NS control group (Po0.01). The OXM level in the intestinal contents of the OXM group was significantly increased compared with that of the GFP negative control group and the NS group (Po0.05). The plasma ghrelin level of the OXM group was significantly decreased compared with that of the GFP and NS groups (Po0.01). Unexpectedly, the ghrelin level of the GFP gr...

show abstract

“…Oxyntomodulin was shown to inhibit pancreatic secretion through the nervous system in rats [58]. While glucagon can depress pancreatic exocrine secretions in normal animals and humans, it is still unclear how glucagon exerts this effect [59].…”

Section: Receptors Involved In the Effect Of Oxyntomodulinmentioning

confidence: 99%

Action and therapeutic potential of oxyntomodulin

Pocai

2014

Molecular Metabolism

153

View full text Add to dashboard Cite

Oxyntomodulin (OXM) is a peptide hormone released from the gut in post-prandial state that activates both the glucagon-like peptide-1 receptor (GLP1R) and the glucagon receptor (GCGR) resulting in superior body weight lowering to selective GLP1R agonists. OXM reduces food intake and increases energy expenditure in humans. While activation of the GCGR increases glucose production posing a hyperglycemic risk, the simultaneous activation of the GLP1R counteracts this effect. Acute OXM infusion improves glucose tolerance in T2DM patients making dual agonists of the GCGR and GLP1R new promising treatments for diabetes and obesity with the potential for weight loss and glucose lowering superior to that of GLP1R agonists.

show abstract

Oxyntomodulin Inhibits Pancreatic Secretion Through the Nervous System in Rats

Cited by 32 publications

References 31 publications

Neural hormonal regulation of exocrine pancreatic secretion

Neural hormonal regulation of exocrine pancreatic secretion

Bifidobacterium as an oral delivery carrier of oxyntomodulin for obesity therapy: inhibitory effects on food intake and body weight in overweight mice

Action and therapeutic potential of oxyntomodulin

Contact Info

Product

Resources

About